CD151 Gene and Protein Expression Provides Independent Prognostic Information for Patients with Adenocarcinoma of the Esophagus and Gastroesophageal Junction Treated by Esophagectomy

Background Esophageal and gastroesophageal junctional (GEJ) adenocarcinoma is one of the most fatal cancers and has the fastest rising incidence rate of all cancers. Identification of biomarkers is needed to tailor treatments to each patient’s tumor biology and prognosis. Methods Gene expression pro...

Full description

Saved in:
Bibliographic Details
Published in:Annals of surgical oncology 2016-12, Vol.23 (Suppl 5), p.746-754
Main Authors: Fisher, Oliver M., Levert-Mignon, Angelique J., Lehane, Christopher W., Botelho, Natalia K., Maag, Jesper L. V., Thomas, Melissa L., Edwards, Melanie, Lord, Sarah J., Bobryshev, Yuri V., Whiteman, David C., Lord, Reginald V.
Format: Article
Language:English
Subjects:
Adenocarcinoma - genetics
Adenocarcinoma - metabolism
Adenocarcinoma - pathology
Adenocarcinoma - therapy
Aged
Biomarkers, Tumor - genetics
Biomarkers, Tumor - metabolism
Chemoradiotherapy, Adjuvant
Esophageal Neoplasms - genetics
Esophageal Neoplasms - metabolism
Esophageal Neoplasms - pathology
Esophageal Neoplasms - therapy
Esophagectomy
Esophagogastric Junction
Female
Gastrointestinal Oncology
Gene Expression
Gene Expression Profiling
Humans
Kaplan-Meier Estimate
Male
Medicine
Medicine & Public Health
Middle Aged
Neoplasm Staging
Oncology
Prognosis
Proportional Hazards Models
Surgery
Surgical Oncology
Survival Rate
Tetraspanin 24 - genetics
Tetraspanin 24 - metabolism
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background Esophageal and gastroesophageal junctional (GEJ) adenocarcinoma is one of the most fatal cancers and has the fastest rising incidence rate of all cancers. Identification of biomarkers is needed to tailor treatments to each patient’s tumor biology and prognosis. Methods Gene expression profiling was performed in a test cohort of 80 chemoradiotherapy (CRTx)-naïve patients with external validation in a separate cohort of 62 CRTx-naïve patients and 169 patients with advanced-stage disease treated with CRTx. Results As a novel prognostic biomarker after external validation, CD151 showed promise. Patients exhibiting high levels of CD151 (≥median) had a longer median overall survival than patients with low CD151 tumor levels (median not reached vs. 30.9 months; p  = 0.01). This effect persisted in a multivariable Cox-regression model with adjustment for tumor stage [adjusted hazard ratio (aHR), 0.33; 95 % confidence interval (CI), 0.14–0.78; p  = 0.01] and was further corroborated through immunohistochemical analysis (aHR, 0.22; 95 % CI, 0.08–0.59; p  = 0.003). This effect was not found in the separate cohort of CRTx-exposed patients. Conclusion Tumoral expression levels of CD151 may provide independent prognostic information not gained by conventional staging of patients with esophageal and GEJ adenocarcinoma treated by esophagectomy alone.
ISSN:1068-9265
1534-4681
DOI:10.1245/s10434-016-5504-9